Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Down 90.6% in January

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 2,565 shares, a drop of 90.6% from the December 31st total of 27,309 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 6,364 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 6,364 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

Institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its stake in shares of Invesco Biotechnology & Genome ETF by 74.5% during the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after buying an additional 245 shares during the period. Allworth Financial LP acquired a new stake in Invesco Biotechnology & Genome ETF during the 2nd quarter worth $54,000. NewEdge Advisors LLC lifted its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the third quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock valued at $62,000 after acquiring an additional 342 shares during the period. Blair William & Co. IL grew its stake in shares of Invesco Biotechnology & Genome ETF by 150.0% during the 3rd quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock worth $70,000 after purchasing an additional 600 shares during the period. Finally, Advisory Services Network LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $82,000.

Invesco Biotechnology & Genome ETF Price Performance

NYSEARCA:PBE traded down $0.89 during trading hours on Wednesday, reaching $82.36. The company had a trading volume of 26,211 shares, compared to its average volume of 8,278. The firm has a market cap of $264.38 million, a PE ratio of 20.44 and a beta of 0.79. The business’s 50 day moving average price is $82.19 and its 200-day moving average price is $74.43. Invesco Biotechnology & Genome ETF has a 1-year low of $54.52 and a 1-year high of $85.73.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.